EVAXION A/S (EVAX) Stock Price & Overview
NASDAQ:EVAX • US29970R3030
Current stock price
The current stock price of EVAX is 3.78 USD. Today EVAX is down by -1.31%. In the past month the price increased by 13.86%. In the past year, price increased by 100%.
EVAX Key Statistics
- Market Cap
- 31.526M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.02
- Dividend Yield
- N/A
EVAX Stock Performance
EVAX Stock Chart
EVAX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to EVAX. When comparing the yearly performance of all stocks, EVAX is one of the better performing stocks in the market, outperforming 90.65% of all stocks.
EVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EVAX. EVAX may be in some trouble as it scores bad on both profitability and health.
EVAX Earnings
EVAX Forecast & Estimates
10 analysts have analysed EVAX and the average price target is 11.99 USD. This implies a price increase of 217.06% is expected in the next year compared to the current price of 3.78.
For the next year, analysts expect an EPS growth of -4.33% and a revenue growth -83.36% for EVAX
EVAX Groups
Sector & Classification
EVAX Financial Highlights
Over the last trailing twelve months EVAX reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 63.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.35% | ||
| ROE | -192.35% | ||
| Debt/Equity | 1.73 |
EVAX Ownership
EVAX Latest News, Press Relases and Analysis
EVAX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.04 | 388.573B | ||
| AMGN | AMGEN INC | 15.4 | 194.674B | ||
| GILD | GILEAD SCIENCES INC | 15.98 | 179.261B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 117.486B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 80.247B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.19 | 42.494B | ||
| INSM | INSMED INC | N/A | 31.024B | ||
| NTRA | NATERA INC | N/A | 28.116B | ||
| BIIB | BIOGEN INC | 11.34 | 27.193B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.76 | 23.669B | ||
| MRNA | MODERNA INC | N/A | 21.299B | ||
| EXAS | EXACT SCIENCES CORP | 341.33 | 19.841B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EVAX
Company Profile
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Company Info
IPO: 2021-02-05
EVAXION A/S
Dr. Neergaards Vej 5F
Hoersholm 1260 DK
CEO: Lars Staal Webner
Employees: 46
EVAXION A/S / EVAX FAQ
Can you describe the business of EVAXION A/S?
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Can you provide the latest stock price for EVAXION A/S?
The current stock price of EVAX is 3.78 USD. The price decreased by -1.31% in the last trading session.
Does EVAXION A/S pay dividends?
EVAX does not pay a dividend.
How is the ChartMill rating for EVAXION A/S?
EVAX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of EVAXION A/S (EVAX) based on its PE ratio?
EVAXION A/S (EVAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).
What is the expected growth for EVAX stock?
The Revenue of EVAXION A/S (EVAX) is expected to decline by -83.36% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is EVAXION A/S worth?
EVAXION A/S (EVAX) has a market capitalization of 31.53M USD. This makes EVAX a Nano Cap stock.